Global Haemophilia Market – Industry Trends and Forecast to 2029

Global Haemophilia Market, By Type (Haemophilia A, Haemophilia B, Haemophilia C, Others), Patient (Pediatric, Adult), Treatment (Medication, Therapy, Fibrin Sealants, Others), Diagnosis (Blood Test, Genetic Tests, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Analysis and Size                              

Haemophilia affects about one in every 5,617 live male births, according to the US Centers for Disease Control and Prevention (CDC). In the United States, between 30,000 and 33,000 men have haemophilia. The severe type of haemophilia A affects more than half of those diagnosed. Haemophilia A affects four times more people than haemophilia B. Haemophilia is a blood disorder that affects people of all races and ethnicities. Haemophilia A, commonly known as classical haemophilia, is a genetic bleeding illness caused by a lack of factor VIII in the blood.

Data Bridge Market Research analyses that the haemophilia market was valued at USD 10.5 billion in 2021 and is expected to reach USD 18.87 billion by 2029, registering a CAGR of 7.60% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Haemophilia is an uncommon disorder in which the clotting of blood is hindered due to a lack of blood-clotting proteins. After an injury, surgery, or tooth extraction, patients with this syndrome have persistent bleeding or oozing. Haemophilia treatment entails the administration of drugs by intravenous or nasal routes to avoid internal bleeding, which can lead to arthritis, joint deterioration, and infection. It is a hereditary bleeding disorder that can cause persistent bleeding or leakage following an injury or surgery. Prolonged bleeding can occur in severe situations after mild trauma or even in the absence of injury.

Haemophilia Market Dynamics

Drivers

• High prevalence rate of haemophilia across the globe

The rise in prevalence rate of haemophilia across the globe will act as a major driver that will result in the expansion of the growth rate of the market. Patients with severe haemophilia require a frequent haemophilia treatment regimen to keep enough clotting factors in their bloodstream to avoid bleeds. Including a global study published in October 2021 by the World Federation of Haemophilia, there were 209,614 persons diagnosed with haemophilia worldwide, with 165,379 haemophilia patients. Furthermore, patients who receive quality care are more likely to have fewer co-morbid diseases and have a decreased risk of serious bleeding. As a result, the ever-increasing number of patients has increased demand for haemophilia therapy, which will raise product adoption rates.

• Surging number of pediatric population

The increasing number of pediatric population is estimated to enhance the market’s growth rate during the forecast period of 2022-2029. The prevalence of haemophilia is steadily rising among pediatric. Haemophilia is expected to affect one out of every 10,000 births, according to the World Federation of Haemophilia (WFH). Pediatric with haemophilia lack enough clotting factors in their blood as they cannot stop bleeding, necessitating the use of specific haemophilia medications to prevent excessive bleeding. A number of government and non-government groups are launching public awareness campaigns about the signs, diagnosis, and treatment of haemophilia in pediatrics. Furthermore, prominent industry players are focusing on developing innovative solutions to minimize the severity of haemophilia in pediatrics, hence accelerating market growth.

Furthermore, surging number of government initiatives to spread awareness will result in the expansion of haemophilia market. Along with this, changing lifestyle of people and growing government favourable initiatives will enhance the growth rate of the market. Another significant factor influencing the growth rate of haemophilia market is the rising healthcare expenditure which helps in improving its infrastructure.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the haemophilia market growth. BioMarin Pharmaceutical Inc. stated in 2021 that it had completed a large phase 3 gene therapy trial in adults with severe haemophilia A in the United States. Over the projection period, such continuous research and innovation initiatives are expected to boost market demand. As a result, the variables listed above are expected to boost product uptake in the country.

• New product launches

Over the projected period, new product launches by industry players in the haemophilia market are estimated to promote new market opportunities. For illustration, the European Commission granted Novo Nordisk marketing approval for 'Esperoct' in Europe in June 2019. Turoctocog alfa pegol, N8-GP, is marketed under the trade name Esperoct and is used to treat haemophilia in adolescents and adults (congenital factor VIII deficiency). Furthermore, Roche Products India Pvt. Ltd released Hemlibra, a haemophilia medication, in India in April 2019. Through Factor VIII inhibitors, it is suggested for preventative therapy of haemophilia patients to reduce the frequency of bleeding episodes.

Moreover, the market's growth is fueled by investment for the development of advanced technologies and increase in the number of emerging markets. These factors will provide beneficial opportunities for the haemophilia market growth.

Restraints/Challenges

• High cost associated with the haemophilia treatment

The high cost associated with the treatment will obstruct the growth rate of haemophilia market during the forecast period of 2022-2029. The average cost of haemophilia treatment is over USD 300,000 per year, according to the National Haemophilia Foundation, which has a substantial influence on operation margins, especially in today's capitated reimbursement environment. Due to the high costs associated with clotting factor therapy, market expansion in emerging nations with comparatively low income levels may be impeded.

On the other hand, the lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the haemophilia market. Additionally, lack of awareness among people and strict government regulations will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This haemophilia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the haemophilia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

After von Willebrand disease, haemophilia is the most common X-linked recessive condition and the most common inherited clotting factor deficiency. Males are more likely to be affected by haemophilia A, however females can be impacted as well. Haemophilia affects about 1 in every 5,000 new-born boys. Haemophilia affects approximately 60% of people. Haemophilia affects people of all races and ethnic groups equally.

Haemophilia market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Haemophilia Market

Due to disruptions in the worldwide supply chain and logistics, the onset of the COVID-19 pandemic had a minor negative influence on the haemophilia treatment market. The impact of the coronavirus outbreak on the sector peaked in early 2020, when people with such disorders were more susceptible to infectious diseases and hence had a higher risk of contracting coronavirus. Several organizations, hospitals, and haematologists, on the other hand, were working hard to manage the COVID-19 public health issue. For instance, in response to the coronavirus outbreak, the American Society of Hematology established a forum for the exchange of useful, precise, and up-to-date information to aid haematologists. As a result, such approaches are predicted to aid in the restoration of treatment volume following the COVID-19 outbreak.

Recent Development

• In February 2020, Novo Nordisk had announced the launch of company’s long-acting recombinant factor VIII product named ESPEROCT. It is used for preventing as well as treating bleeding in individuals with haemophilia A. The new medication is intended for routine prophylaxis to limit the number of bleeding episodes, on-demand treatment, bleeding episode control, and perioperative bleeding management.

Global Haemophilia Market Scope

The haemophilia market is segmented on the basis of type, treatment, patient, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Medication
• Desmopressin
• Emicizumab
• Anti-fibrinolytics
• Therapy
• Replacement Therapy
• ITI Therapy
• Gene Therapy
• Fibrin Sealants
• Others

Diagnosis

• Blood Test
• Genetic Tests
• Others

Patient

• Pediatric
  • 0 to 4
  • 5 to 13
  • 14 to18
• Adult
  • 19 to 44
  • 45+

Type

• Haemophilia A
• Haemophilia B
• Haemophilia C
• Others

Route of Administration

• Oral
• Injectable
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Haemophilia Market Regional Analysis/Insights

The haemophilia market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, patient, route of administration, end-users and distribution channel as referenced above.

The countries covered in the haemophilia market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the haemophilia market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing demand for specific treatment and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, high prevalence of bleeding disorders and rise in adoption of newer technologies will further propel the market’s growth rate in this region.

Europe is expected to be the fastest growing region during the forecast period of 2022-2029 due to growing cases of haemophilia in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Haemophilia Market Share Analysis

The haemophilia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to haemophilia market.

Some of the major players operating in the haemophilia market are:

• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Merck & Co., Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Baxter (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Grifols, S.A. (Spain)
• CSL (U.S.)
• BioMarin (U.S.)
• Spark Therapeutics, Inc. (U.S.)
• Chugai Pharmaceutical Co. Ltd. (Japan)
• Octapharma AG (Switzerland)
• Novo Nordisk A/S (Denmark)
• Biogen (U.S.)
• Genentech Inc. (U.S.)
• Bayer AG (Germany)
• Ferring B.V. (Switzerland)